Literature DB >> 7073268

Pharmacokinetics of ceforanide.

S Ripa, F La Rosa, A Ghezzi, M Prenna, M Pfeffer.   

Abstract

The pharmacokinetic of ceforanide, a new parenteral cephalosporin antibiotic, were examined at intravenous and intramuscular doses of 250, 500, and 1,000 mg in healthy male volunteers. Over the above dosing range, ceforanide pharmacokinetics were essentially linear, with plasma clearances varying from 2.2 to 2.5 liters/h. The best present overall estimate of the drug's half-life was 2.9 h. Intramuscular ceforanide was 100% bioavailable, Peak intravenous serum levels were 39, 71, and 135 micrograms/ml at the end of 30-min infusions of 250, 500, and 1,000 mg; after intramuscular injections of 250, 500, and 1,000 mg, the respective peak serum levels were 21, 38, and 69 micrograms/ml. From 80 to 85% of the above doses were eliminated as unchanged.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7073268      PMCID: PMC181880          DOI: 10.1128/AAC.21.2.323

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

2.  Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin.

Authors:  R D Smyth; M Pfeffer; A Glick; D R Van Harken; G H Hottendorf
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

3.  Human pharmacokinetics of a new braod-spectrum parenteral cephalosporin antibiotic, ceforanide.

Authors:  M Pfeffer; R C Gaver; D R Van Harken
Journal:  J Pharm Sci       Date:  1980-04       Impact factor: 3.534

4.  Laboratory evaluation of BL-S786, a cephalosporin with broad-spectrum antibacterial activity.

Authors:  F Leitner; M Misiek; T A Pursiano; R E Buck; D R Chisholm; R G DeRegis; Y H Tsai; K E Price
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

5.  In vitro and in vivo studies with BL-S786, cefoxitin, and cefamandole.

Authors:  S Shadomy; G Wagner; M Carver
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

  5 in total
  5 in total

Review 1.  Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D M Campoli-Richards; T E Lackner; J P Monk
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

2.  Twice-daily intramuscular ceforanide therapy of Staphylococcus aureus endocarditis in parenteral drug abusers.

Authors:  R L Greenman; S M Arcey; D A Gutterman; R M Zweig
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

3.  Intraoperative ceforanide pharmacokinetics and protein binding.

Authors:  J T DiPiro; S M Bayoumi; J J Vallner; R R Nesbit; R Gokhale; J P Rissing
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

4.  In vitro antimicrobial activity of eight new beta-lactam antibiotics against penicillin-resistant Neisseria gonorrhoeae.

Authors:  S B Kerbs; J R Stone; S W Berg; W O Harrison
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

5.  Performance of a diffusional clearance model for beta-lactam antimicrobial agents as influenced by extravascular protein binding and interstitial fluid kinetics.

Authors:  J C Fleishaker; P J McNamara
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.